In a significant development, Monte Rosa Therapeutics, a biotechnology company based in Boston, has finalized a highly lucrative global exclusive development and commercialization license agreement with Novartis valued at up to $2.1 billion on October 28, 2024. Monte Rosa Therapeutics is focused on
MilliporeSigma, a prominent player in the life sciences sector, has launched a transformative $76 million investment dedicated to expanding its ADC (antibody-drug conjugates) manufacturing capabilities at its St. Louis, Missouri facility. This monumental investment encapsulates the extensive
Artificial Intelligence (AI) has the potential to revolutionize drug discovery and development, offering numerous advantages that could transform current practices in the biopharmaceutical industry. By merging Accenture's advanced capabilities in AI scaling with the innovative ITO™ platform
In a pioneering move to advance cancer treatment, Ryvu Therapeutics and nCage Therapeutics have announced a research collaboration aimed at developing a next-generation antibody-drug conjugate (ADC) platform. This partnership promises to leverage nCage's TRAP cage platform, a novel drug delivery
Biond Biologics Ltd., a private biopharmaceutical company, has entered into a partnership with Merck KGaA, Darmstadt, Germany, to support a Phase 1 clinical trial aimed at treating patients with unresectable or metastatic solid tumors. This clinical trial, designated as BND-35-001 (NCT06274437),
The recent FDA approval of Protega Pharmaceuticals Inc.'s ROXYBOND (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet marks a significant milestone in managing severe pain where alternative treatments fall short. ROXYBOND 10 mg stands out as the first FDA-approved abuse-deterrent IR
